Alamar Biosciences director reports no holdings

A newly reported director at Alamar Biosciences has filed an initial Form 3 with no transactions or holdings disclosed.

Rhea-AI Filing Summary

Alamar Biosciences, Inc. (ALMR) has a new insider disclosure, as Robert P. Ragusa, serving as a director, filed an initial Form 3 reporting his status as an insider. The filing shows no reported transactions or holdings of Alamar Biosciences securities at this time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for ALMR disclose about Robert P. Ragusa?

The Form 3 identifies Robert P. Ragusa as a director of Alamar Biosciences, Inc. It is an initial statement of insider status and does not report any transactions or holdings of the company’s securities.

Are any share transactions reported in this ALMR Form 3?

No. The filing’s transaction data show no reported purchases, sales, or other transactions by Robert P. Ragusa in Alamar Biosciences, Inc. securities as of this filing.

Does the ALMR Form 3 show any current holdings by the director?

No. The Form 3 indicates no holdings entries for Alamar Biosciences, Inc. securities by Robert P. Ragusa at the time of this initial filing.

What insider role is reported for Robert P. Ragusa at Alamar Biosciences (ALMR)?

Robert P. Ragusa is reported as a director of Alamar Biosciences, Inc. He is not identified as an officer or a ten percent owner in this Form 3.

Does the ALMR Form 3 mention any Rule 10b5-1 trading plan?

No. The available data show no indication that this filing is associated with a Rule 10b5-1 trading plan for Robert P. Ragusa.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 04:33 PM EDT Accepted by SEC EDGAR 09/03/2026 - 04:26 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

RAGUSA ROBERT P

(Last) (First) (Middle)

C/O ALAMAR BIOSCIENCES, INC.

47071 BAYSIDE PARKWAY

(Street)

FREMONT CALIFORNIA 94538

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/01/2026

3. Issuer Name and Ticker or Trading Symbol
Alamar Biosciences, Inc. [ ALMR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Timothy White, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)